-
EP4195941
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4195941
| EP4195941 - IMMUNOMODULATION FORMULATIONS AND RELATED METHODS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 18.09.2025 Database last updated on 07.03.2026 | |
| Former | Request for examination was made Status updated on 19.05.2023 | ||
| Former | The international publication has been made Status updated on 21.02.2022 | Most recent event Tooltip | 16.10.2025 | New entry: Reply to examination report | Applicant(s) | For all designated states Vickers, Alexander 4101 Centurion Way Addison, TX 75001 / US | [2023/25] | Inventor(s) | 01 /
see applicant ... | [2023/25] | Representative(s) | Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham, West Midlands B16 8QQ / GB | [2023/25] | Application number, filing date | 21856830.1 | 13.08.2021 | [2023/25] | WO2021US46032 | Priority number, date | US202063065301P | 13.08.2020 Original published format: US 202063065301 P | [2023/25] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022036278 | Date: | 17.02.2022 | Language: | EN | [2022/07] | Type: | A1 Application with search report | No.: | EP4195941 | Date: | 21.06.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.02.2022 takes the place of the publication of the European patent application. | [2023/25] | Search report(s) | International search report - published on: | US | 17.02.2022 | (Supplementary) European search report - dispatched on: | EP | 02.10.2024 | Classification | IPC: | A23L2/52, A23L33/105, A61K9/00, A61K9/107, A61K9/48, A61K31/045, A61K31/05, A61K31/352, A61K36/185, A61K36/67, A61K45/06, A61K47/24 | [2024/44] | CPC: |
A61K45/06 (EP,IL);
A61K9/0053 (EP,IL,KR);
A61K31/658 (EP,KR,US);
A61K31/015 (EP);
A61K31/05 (IL);
A61K31/352 (IL);
A61K36/3482 (EP,IL,KR,US);
A61K36/67 (EP,IL,KR,US);
A61K47/14 (KR,US);
A61K47/18 (KR,US);
A61K47/22 (KR,US);
A61K47/24 (EP,IL,US);
A61K9/06 (EP);
A61K9/107 (EP,IL,KR,US);
A61K9/1075 (EP);
| C-Set: |
A61K31/015, A61K2300/00 (EP);
A61K31/658, A61K2300/00 (EP);
A61K36/185, A61K2300/00 (EP);
A61K36/67, A61K2300/00 (EP) |
| Former IPC [2023/25] | A23L2/52, A23L33/105, A61K9/00, A61K9/107, A61K9/48, A61K31/045 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/25] | Title | German: | IMMUNMODULATIONSFORMULIERUNGEN UND ZUGEHÖRIGE VERFAHREN | [2023/25] | English: | IMMUNOMODULATION FORMULATIONS AND RELATED METHODS | [2023/25] | French: | FORMULATIONS D'IMMUNOMODULATION ET PROCÉDÉS ASSOCIÉS | [2023/25] | Entry into regional phase | 08.03.2023 | National basic fee paid | 08.03.2023 | Search fee paid | 08.03.2023 | Designation fee(s) paid | 08.03.2023 | Examination fee paid | Examination procedure | 01.03.2022 | Request for preliminary examination filed International Preliminary Examining Authority: US | 08.03.2023 | Examination requested [2023/25] | 22.04.2025 | Amendment by applicant (claims and/or description) | 22.04.2025 | Date on which the examining division has become responsible | 17.09.2025 | Despatch of a communication from the examining division (Time limit: M04) | 15.10.2025 | Reply to a communication from the examining division | Fees paid | Renewal fee | 29.08.2023 | Renewal fee patent year 03 | 13.08.2024 | Renewal fee patent year 04 | 01.09.2025 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] EP3417846 (GIFAR SRL et al.) | [A] WO2019135224 (ICDPHARMA LTD et al.) | [A] US2016051510 (ALLEN ERIC et al.) | [IY] EP3409275 (NEILOS S R L et al.) [I] 1-15 * paragraphs [0057] - [0068] - [ 0007] , [0024] *[Y] 1-15 | International search | [Y] WO2019136351 (ALTUS LABS LLC et al.) [Y] 1-13 * entire document * | [Y] WO2019104291 (LAAU PONO et al.) [Y] 1-13 * entire document * | [Y] WO2019135224 (ICDPHARMA LTD et al.) [Y] 7 * entire document * | [Y] US2002086042 (DELRIEU PASCAL E et al.) [Y] 11-13 * entire document * | [A] US2011195096 (KINDLER SETH et al.) [A] 1-20 * entire document * | [P, A] WO2021033149 (BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD et al.) [P, A] 1-20 * entire document * | [Y] BO WANG, ANNA KOVALCHUK, DONGPING LI, YAROSLAV ILNYTSKYY, IGOR KOVALCHUK, OLGA KOVALCHUK: "In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues", XP055765023, Retrieved from the Internet DOI: http://dx.doi.org/10.20944/preprints202004.0315.v1 | [A] GIUSEPPE ESPOSITO; MARCELLA PESCE; LUISA SEGUELLA; WALTER SANSEVERINO; JIE LU; CHIARA CORPETTI; GIOVANNI SARNELLI: "The potential of cannabidiol in the COVID19 pandemic", BRITISH JOURNAL OF PHARMACOLOGY, vol. 177, no. 21, 16 July 2020 (2020-07-16), UK , pages 4967 - 4970, XP071172311, ISSN: 0007-1188, DOI: 10.1111/bph.15157 [A] 1-20 DOI: http://dx.doi.org/10.1111/bph.15157 | Examination | BO WANG ET AL: "In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues", 17 April 2020 (2020-04-17), XP055765023, Retrieved from the Internet DOI: http://dx.doi.org/10.20944/preprints202004.0315.v1 | ROSSI FRANCESCA ET AL: "Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 11, 27 May 2020 (2020-05-27), pages 1 - 16, XP055879942, DOI: 10.3390/ijms21113809 [A] 1-14 DOI: http://dx.doi.org/10.3390/ijms21113809 | GIUSEPPE ESPOSITO ET AL: "The potential of cannabidiol in the COVID-19 pandemic", BRITISH JOURNAL OF PHARMACOLOGY, WILEY-BLACKWELL, UK, vol. 177, no. 21, 16 July 2020 (2020-07-16), pages 4967 - 4970, XP071172311, ISSN: 0007-1188, DOI: 10.1111/BPH.15157 [A] 1-14 DOI: http://dx.doi.org/10.1111/bph.15157 | by applicant | EP3417846 | WO2019135224 | US2016051510 | EP3409275 | WANG ET AL.: "In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues", EUROPE PMC, 2020 | ESPOSITO ET AL.: "The potential of cannabidiol in the COVID-19 pandemic", BRITISH JOURNAL OF PHARMACOLOGY, vol. 177, no. 21, 2020, pages 4967 - 4970 [A] 1-20 | ROSSI ET AL.: "Cannabinoid receptor type 2: a possible target in SARS-CoV-2 (CoV-19) infection?", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 11, 2020, pages 3809 | EP3417846 | WO2019135224 | US2016051510 | EP3409275 | WANG ET AL.: "In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues", EUROPE PMC, 2020 [Y] 1-15 | ESPOSITO ET AL.: "The potential of cannabidiol in the COVID-19 pandemic", BRITISH JOURNAL OF PHARMACOLOGY, vol. 177, no. 21, 2020, pages 4967 - 4970 [Y] 1-15 | ROSSI ET AL.: "Cannabinoid receptor type 2: a possible target in SARS-CoV-2 (CoV-19) infection?", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 11, 2020, pages 3809, XP055879942, DOI: 10.3390/ijms21113809 [Y] 1-15 DOI: http://dx.doi.org/10.3390/ijms21113809 |